arrow_back Back to App

Drug Safety: Monitoring Supply Chains and Preventing Shortages

This act aims to ensure Americans always have access to essential medicines. The government will create and update a list of critical drugs, assess risks in their supply chains, and monitor where drug ingredients come from to prevent shortages and protect public health.
Key points
The government will create and regularly update a list of essential medicines, including those critical for public health emergencies or for patients with chronic conditions.
A risk assessment of these medicine supply chains will be conducted to identify those most vulnerable to shortages, especially those from foreign sources or single suppliers.
A system will be established to map drug supply chains, tracking production from raw materials to finished products, using data analytics to identify vulnerabilities.
Cybersecurity measures will be implemented to protect sensitive data related to drug production and supply.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_4191
Sponsor: Rep. Matsui, Doris O. [D-CA-7]
Process start date: 2025-06-26
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

MAPS Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_4191.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-06-26.

What are the main provisions?

Key points include:

  • The government will create and regularly update a list of essential medicines, including those critical for public health emergencies or for patients with chronic conditions.
  • A risk assessment of these medicine supply chains will be conducted to identify those most vulnerable to shortages, especially those from foreign sources or single suppliers.
  • A system will be established to map drug supply chains, tracking production from raw materials to finished products, using data analytics to identify vulnerabilities.
  • Cybersecurity measures will be implemented to protect sensitive data related to drug production and supply.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Matsui, Doris O. [D-CA-7].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health Security